StockNews.AI
BBIO
StockNews.AI
54 days

BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET

1. BridgeBio will host an investor webinar on July 11, 2025. 2. Webinar will cover limb-girdle muscular dystrophy type 2I/R9 and its unmet needs. 3. Dr. Wicklund will present on the disease burden and current treatment standards. 4. Details on BBP-418's progress and Phase 3 analysis expectations will be shared. 5. Webcast replay will be available for 30 days post-event on BridgeBio's website.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming webinar may attract investor interest, particularly due to upcoming trial results.

How important is it?

The webinar's focus on LGMD2I/R9 and BBP-418 could significantly influence operator sentiment and stock price.

Why Short Term?

Expectations for upcoming results from the Phase 3 analysis may lead to immediate interest and volatility.

Related Companies

MDGLSNYSRPT
June 26, 2025 07:30 ET  | Source: BridgeBio Pharma, Inc. PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Friday, July 11, 2025 at 8:00 am ET with Matthew Wicklund, M.D., FAAN, Professor of Neurology and Vice Chair for Research, Department of Neurology at the University of Texas (UT) Health Science Center San Antonio. Dr. Wicklund will provide an overview of limb-girdle muscular dystrophy (LGMD), specifically focusing on the disease burden, standard of care and unmet needs for those with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) (FKRP-related). He serves as director for the UT Health San Antonio MDA Multidisciplinary Care Center and is a member of the Limb-girdle Muscular Dystrophy Clinical Research Network and the Neuromuscular Study Group. Dr. Wicklund has participated in over 35 multi-center clinical trials in the areas of muscular dystrophy, ALS, and myasthenia gravis and has over 200 published articles, chapters and abstracts. In addition to Dr. Wicklund, executive members of the LGMD2I/R9 program will review the progress of BBP-418 to date and discuss expectations for the Phase 3 interim analysis results expected in the second half of 2025. To access the live webcast of BridgeBio’s investor webinar, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at http://investor.bridgebio.com. A replay of the webcast will be available on the BridgeBio website for 30 days following the event. About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter, Facebook, and YouTube. BridgeBio Media Contact:Bubba Murarka, Executive Vice Presidentcontact@bridgebio.com   (650)-789-8220 BridgeBio Investor Contact:Chinmay Shukla, VP Strategic Financeir@bridgebio.com

Related News